Johnson & Johnson
Statements
Segments
US companies must disclose in their mandatory reports how revenue breaks down across business segments, regions and product lines. We read that breakdown for you straight from the annual and quarterly reports (10-K and 10-Q) of Johnson & Johnson (JNJ). It shows which part of the business is growing — and which one is holding it back.
Revenue by business segment
| Segment | Q2 2023 | Q3 2023 | Q4 2023 | Q4 2023 | Q1 2025 | Q2 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|---|---|---|
| Innovative Medicine | $13.41B 64.2% | $13.73B 63.8% | $13.89B 65.1% | $13.72B 64.1% | $13.87B 63.4% · +3.4% | $15.20B 64.0% · +10.7% | $15.43B 64.1% · +11.0% | $16.38B 64.7% · +19.4% |
| MedTech | $7.48B 35.8% | $7.79B 36.2% | $7.46B 34.9% | $7.67B 35.9% | $8.02B 36.6% · +7.2% | $8.54B 36.0% · +9.7% | $8.64B 35.9% · +15.8% | $8.93B 35.3% · +16.3% |
Large figure: segment revenue. Below it the share of revenue in that period and the change against the prior year.
Segment and region names are the ones the company itself uses and are shown as reported. Change and share refer to revenue.
Data as of: August 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · Segment figures: SEC EDGAR (10-K/10-Q reports)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.